Get started
Work

Osimertinib vs standard of care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA

Year: 2017
Type: article
DOI: 10.1093/annonc/mdx671.002
Authors: Y. Ohe, S. Ramalingam, T. Reungwetwattana, B. Chewaskulyong, A. Dechaphunkul, K.H. Lee, F. Imamura, N. Nogami, Y. Cheng, B.C. Cho, E.K. Cho, J. Vansteenkiste, P.J. Voon, C. Zhou, J. Gray, R. Hodge, Y. Rukazenkov, J -C Soria
Institutions: National Cancer Center Hospital, Emory University, Winship Cancer Institute, Mahidol University, Ramathibodi Hospital, Chiang Mai University, Prince of Songkla University, Chungbuk National University, Chungbuk National University Hospital, Osaka International Cancer Institute, Shikoku Cancer Center, Jilin Province Tumor Hospital, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Gachon University Gil Medical Center, Universitair Ziekenhuis Leuven, KU Leuven, Sarawak General Hospital, Tongji University, Moffitt Cancer Center, AstraZeneca (United Kingdom), Institut Gustave Roussy
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2769067535
FWCI: 0.204
Cites:
Cited by: 1
Related to: 10